AntiBKV is designed to neutralise BKV infection in kidney transplant recipients. Credit: Pixel-Shot / shutterstock.

Swiss biotechnology company Memo Therapeutics has raised Sfr25m ($27.6m) in a Series C financing round led by Pureos Bioventures.

The funding round included contributions from the company’s existing investors Red Alpine, GF Group, Fresenius Medical Care Ventures, Verve Ventures, Schroders Capital, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Memo Therapeutics will use the funding to complete Phase II clinical development of AntiBKV for BK polyomavirus (BKV) infection in renal transplant patients.

AntiBKV is designed to neutralise BKV infection in kidney transplant recipients.

Memo Therapeutics expects Phase II clinical data on the drug next year.

See Also:

The new funding will also support the company’s preparation to increase CMC manufacturing of AntiBKV before its Phase III clinical trial and potential entry into the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, Memo Therapeutics will use the proceeds to advance its current antibody pipeline.

Memo Therapeutics board of directors chairman Elias Papatheodorou said: “With these new funds, we are in an optimal position to complete a multi-centre Phase II study with AntiBKV, a treatment option that could dramatically improve the lives of renal transplant patients.

“Importantly, we will also scale up CMC manufacturing of AntiBKV to ensure we have product ready for further clinical evaluation and in anticipation of a potential launch in 2025.

“On behalf of Memo Therapeutics, I’d like to welcome our new investor, Pureos Bioventures. We are also fortunate to have the long-term support of our existing investors who share our goal to develop best-in-class therapeutic antibodies for difficult to treat diseases.”

BKV infection poses a substantial risk post-transplantation, leading to severe impacts on graft function and patients’ survival.

Earlier this year, Memo Therapeutics began enrolling subjects in a Phase II/III trial of AntiBKV to treat BKV infection in renal transplant patients.

The trial involves administering four 1,000mg doses of AntiBKV every four weeks to participants against a placebo.